指南与共识泌尿生殖腹部MR

MRI用于前列腺癌筛查:ESUR前列腺MRI工作组见解

Prostate cancer screening with MRI: insights from the ESUR Prostate MRI Working Group.
PubMed 文献 · Eur Radiol · 2026-10-15

本文为ESUR前列腺MRI工作组特别报告,概述MRI在前列腺癌筛查中的证据与潜在作用。基于MRI的筛查策略可提高临床显著前列腺癌检出并减少不必要活检及非显著疾病诊断,但长期结局数据有限。双参数MRI因采集时间短、操作简单、成本低更适合筛查。

要点

  • 双参数MRI应作为筛查首选方案以提高可行性。
  • MRI可提高临床显著前列腺癌检出并减少不必要活检。
  • MRI整合筛查的长期结局(死亡率、间期癌率)数据有限。
英文原文(摘要)· 点击展开

Prostate-specific antigen (PSA)-based screening for prostate cancer (PCa) remains controversial due to uncertain long-term benefits, overdiagnosis, and overtreatment of indolent disease. Magnetic resonance imaging (MRI) has transformed the diagnostic pathway of PCa and is increasingly explored as a screening tool. This special report from the ESUR Prostate MRI Working Group provides an overview of current evidence and insights into the potential role of MRI in PCa screening. MRI-based screening strategies appear to improve detection of clinically significant PCa while reducing unnecessary biopsies and diagnoses of non-significant disease, though long-term outcome data, including mortality impact and interval cancer rates, remain limited. Biparametric MRI is particularly suited for screening due to its shorter acquisition time, reduced operational complexity, and lower costs compared with multiparametric MRI. Two main implementation approaches have emerged: MRI-first pathways, which maximise detection but require substantial resources, and risk-stratified strategies, in which MRI is used after initial assessment (e.g. PSA), potentially offering greater feasibility and cost-effectiveness. Evidence from large trials supports integrating MRI into screening pathways, particularly as a reflex test after PSA screening, although uncertainties remain regarding optimal protocols, interpretation thresholds, follow-up strategies, and long-term outcomes. Key barriers include limited MRI capacity, economic considerations, and the need for standardisation and quality assurance. Advances in artificial intelligence may further enhance efficiency. Overall, MRI has the potential to improve the balance between benefits and harms in PCa screening, but further evidence is required to define its optimal implementation. KEY POINTS: Question Can prostate MRI be effectively integrated into population-based prostate cancer screening pathways? Findings MRI-based screening improves detection of csPCa while reducing unnecessary biopsies; biparametric MRI should be the protocol of choice to enhance feasibility, although optimal implementation and long-term outcomes remain uncertain. Clinical relevance MRI may overcome key limitations of PSA-based screening by enhancing the detection of clinically significant prostate cancer while reducing harms such as overdiagnosis and unnecessary biopsies.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Brembilla G, Messina E, Barret T, et al. Prostate cancer screening with MRI: insights from the ESUR Prostate MRI Working Group. Eur Radiol. 2026. PMID: 42878808. doi:10.1007/s00330-026-12863-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。